Podcasts about HLA

Í þættinum í dag komu Ólafur og Andri saman til að ræða um þriðju heimsstyrjöldina sem sögulegt fyrirbæri, þ.e. stríðið sem aldrei varð á milli Bandaríkjanna og Sovétríkjanna á síðari hluta síðustu aldar. Kalda stríðið var hugmyndafræðileg barátta tveggja ofurvelda sem skiptu heiminum á milli sín eftir endalok seinni heimsstyrjaldar. Í hálfa öld stóðu vígvélar NATO og Varsjárbandalagsins andspænis hverri annarri sitt hvoru megin við járntjaldið og lögðu á ráðin. Í þessum tvöfalda þætti ræða Söguskoðunarmenn um kalda stríðið og undirbúninginn fyrir þriðju heimsstyrjöldina sem kom sem betur fer ekki.Hlaðvarpið Söguskoðun má nálgast hér:Soguskodun.com | soguskodun@gmail.comEinnig á Facebook og Youtube. Hægt er að styrkja hlaðvarpið með því að bjóða okkur upp á kaffibolla.

Í þættinum í dag komu Ólafur og Andri saman til að ræða um þriðju heimsstyrjöldina sem sögulegt fyrirbæri, þ.e. stríðið sem aldrei varð á milli Bandaríkjanna og Sovétríkjanna á síðari hluta síðustu aldar. Kalda stríðið var hugmyndafræðileg barátta tveggja ofurvelda sem skiptu heiminum á milli sín eftir endalok seinni heimsstyrjaldar. Í hálfa öld stóðu vígvélar NATO og Varsjárbandalagsins andspænis hverri annarri sitt hvoru megin við járntjaldið og lögðu á ráðin. Í þessum tvöfalda þætti ræða Söguskoðunarmenn um kalda stríðið og undirbúninginn fyrir þriðju heimsstyrjöldina sem kom sem betur fer ekki.Hlaðvarpið Söguskoðun má nálgast hér:Soguskodun.com | soguskodun@gmail.comEinnig á Facebook og Youtube. Hægt er að styrkja hlaðvarpið með því að bjóða okkur upp á kaffibolla.

In this special live episode of Girls On Film, host Anna Smith sits down with the creative team behind Hedda, the daring new film from acclaimed director Nia DaCosta, also known for Candyman and The Marvels. Recorded live on 13 October 2025 at Picturehouse Central, this Q&A follows a screening of Hedda - a bold and contemporary reimagining of Henrik Ibsen's classic play Hedda Gabler. The film follows the daughter of a general as she navigates a home she never wanted, a marriage that confines her, and the haunting return of a former lover. Joining Anna on stage are director Nia DaCosta and cast members Tessa Thompson, Nina Hoss, and Imogen Poots, who discuss the film's exploration of race and gender, as well as the creative process of reinventing one of literature's most complex and fascinating women for modern audiences. Hedda is in UK cinemas as of 24 October 2025, and on Prime Video globally on 29 October 2025 Thank you to Amazon MGM Studios for partnering with us on this episode. Become a patron of Girls On Film on Patreon here: www.patreon.com/girlsonfilmpodcast Follow us on socials: www.instagram.com/girlsonfilm_podcast/ www.facebook.com/girlsonfilmpodcast www.twitter.com/GirlsOnFilm_Pod www.twitter.com/annasmithjourno Watch Girls On Film on the BFI's YouTube channel: www.youtube.com/playlist?list=PLX…L89QKZsN5Tgr3vn7z Girls On Film is an HLA production. Host: Anna Smith Executive Producer: Hedda Lornie Archbold Producer: Negin Nia Intern: Ruby Bradshaw Podcast Cover Image: Amy Webster Audio Editor: Elliana Jay Hamer © HLA Agency

In this episode of Girls On Film, we bring you a live-recorded Q&A from our Girls On Film BFI LFF For Free panel, recorded on Thursday, 16 October at 2:00 PM at BFI Southbank. Host Anna Smith speaks with: - Iain Forsyth and Jane Pollard, directors and co-screenwriters on Broken English, an inventive and soulful documentary portrait of cultural icon Marianne Faithfull. - Shih-Ching Tsou, director and co-screenwriter, on Left-Handed Girl, a powerful story following a family of women returning to Taipei to begin a new chapter in their lives. Later in this episode, Anna chats with Sandra Lipski, founder and director of the Evolution Mallorca International Film Festival, joining us online from sunny Mallorca! Set against the stunning backdrop of Palma de Mallorca, the festival has become renowned for its creative energy, vibrant international community, and commitment to connecting cultures through film. Sandra shares insights into what's in store for this year's festival and how it has evolved since its early days. The Girls On Film Women in Leadership panel in Mallorca is on Sunday 26 October at the Es Baluard Museum in Palma de Mallorca. The panel this year will include: - Sarah Brocklehurst: BAFTA-nominated producer. - Abi Harris: founder of Altitude Management. - Alex Buruonova: writer and director, whose film Satisfaction is playing at the festival. Learn more about the festival and our panel here: https://www.evolutionfilmfestival.com Become a patron of Girls On Film on Patreon here: www.patreon.com/girlsonfilmpodcast Follow us on socials: www.instagram.com/girlsonfilm_podcast/ www.facebook.com/girlsonfilmpodcast www.twitter.com/GirlsOnFilm_Pod www.twitter.com/annasmithjourno Watch Girls On Film on the BFI's YouTube channel: www.youtube.com/playlist?list=PLX…L89QKZsN5Tgr3vn7z Girls On Film is an HLA production. Host: Anna Smith Executive Producer: Hedda Lornie Archbold Producer: Negin Nia Intern: Ruby Bradshaw Audio Editor: Benjamin Cook Podcast Cover Image: Ruby Bradshaw Principal Partners: Vanessa Smith and Peter Brewer © HLA Agency

TWiV reviews continuing US measles outbreak, host and genetic variations that regulate antibody responses to hepatitis C virus, and varicella-zoster reactivation and the risk of dementia. Hosts: Vincent Racaniello, Alan Dove, Brianne Barker, and Angela Mingarelli Subscribe (free): Apple Podcasts, RSS, email Become a patron of TWiV! Links for this episode Support science education at MicrobeTV Mass firings at CDC (Time) Measles cases continue to climb in US (NPR) Immune 100 at The Incubator (Eventbrite) Viral and host variations modulate antibody responses against HCV (Cell Rep) VZV reactivation and risk of dementia (Nature Med) Taking a shot at dementia (TWiV 1207) Demented and crass (TWiV 1249) Letters read on TWiV 1263 Timestamps by Jolene Ramsey. Thanks! Weekly Picks Angela – ‘Am I redundant?': how AI changed my career in bioinformatics Brianne – OpenSpace and their YouTube Channel Alan – Coral City Camera – live view of a reef in Biscayne Bay, FL (and NPR story on it). Vincent – Neck pain relief exercises with Dr. Adam Fields Listener Pick Greg – AI: What could go wrong? and An AI System With Detailed Diagnostic Reasoning Makes Its Case Intro music is by Ronald Jenkees Send your virology questions and comments to twiv@microbe.tv Content in this podcast should not be construed as medical advice.

This episode of Girls On Film is dedicated to BAFTA and Oscar contender, The Second Time Around. The film tells a complex, sensitive, universal story, and you can watch it on Channel 4 now. Anna talks to the two stars of the film: Caroline Goodall, best known for films like The Princess Diaries with Anne Hathaway, and her two collaborations with Steven Spielberg, in Hook alongside Robin WIlliams - and in Schindler's List. And Hannah Onslow, who featured alongside Olivia Colman in Empire of Light directed by Sam Mendes, and starred in the BBC's This City Is Ours alongside Sean Bean. Hannah can currently be seen in Noah Baumbach's new film Jay Kelly. Anna also talks to the writer and director, Jack Howard, and to executive producer Hedda Lornie Archbold, who also exec produces this podcast. And finally Anna talks to Rita Hirani, the CEO of MindOut, the mental health charity for the LGBTQ community, who proudly partner with The Second Time Around. Olivia Colman said: “It's a haunting and captivating short that lingers long after it ends. It unsettles you at first, then reveals an unexpected tenderness. An extraordinary depth of story told in just ten minutes." Sign up to the Girls On Film newsletter below: http://eepurl.com/iEKaM-/ or email girlsonfilmsocial@gmail.com to be signed up. Become a patreon of Girls On Film on Patreon here: www.patreon.com/girlsonfilmpodcast Follow us on socials: www.instagram.com/girlsonfilm_podcast/ www.facebook.com/girlsonfilmpodcast www.twitter.com/GirlsOnFilm_Pod www.twitter.com/annasmithjourno Watch Girls On Film on the BFI's YouTube channel: www.youtube.com/playlist?list=PLX…L89QKZsN5Tgr3vn7z Girls On Film is an HLA production. Host: Anna Smith Executive Producer: Hedda Lornie Archbold, who also produced this episode Intern: Ruby Bradshaw Principal Partners Vanessa Smith and Peter Brewer, Thanks to our sponsors for this episode, Lilac Grove Entertainment. © HLA Agency

Hlaðvarpið Komið gott með Ólöfu Skaftadóttur og Kristínu Gunnarsdóttur hefur vakið mikla athygli, enda hlífa þær stöllur fáum og láta gamminn geysa um menn og málefni dagsins. Ólöf kom í fimmu í Fram og til baka og í anda Komið gott talaði hún um fimm atriði í íslensku samfélagi sem henni finnst mæta of lítilli andstöðu. Þetta var tölvustóllinn, Kennarasambandið, íþróttir sem stuðla að ótímabærri örorku, meðalmennskan og vínsmökkun. Svo kíktum við á það sem gerðist á deginum

Í þættinum í dag fjalla Ólafur og Andri um íslam og hinar ýmsu hreyfingar og trúfélög innan íslamstrúar. Íslam er næstfjölmennustu trúarbrögð heims með yfir tvo milljarða fylgjendur. Eftir landvinninga og trúboð Múhameðs spámanns á 7. öld og útþennslu kalífadæmisins klofnaði hreyfingin fljótt í tvær höfuðgreinar, súnní og sjía íslam. Síðan þá hafa margar hreyfingar og hópar komið fram, eins og drúsar, alavítar, súfistar, alevistar, wahabistar, og svo mætti áfram telja.Hlaðvarpið Söguskoðun má nálgast hér:Soguskodun.com | soguskodun@gmail.comEinnig á Facebook og Youtube. Hægt er að styrkja hlaðvarpið með því að bjóða okkur upp á kaffibolla.

On this episode of Girls On Film, Anna Smith sits down with the creative team behind the British-Italian film Brides, which is the directorial debut of Nadia Fall. They discuss teenage friendship, the inspirations and themes that shaped the story, and they touch on the international collaboration behind the production. Brides follows two British Muslim teenagers, Doe and Muna, as they leave the UK for Syria in search of freedom, belonging, and purpose. Inspired by real events, the film offers a sensitive and gripping look at identity, friendship, and the search for meaning in complex circumstances. Joining Anna for a live Q&A panel are actor Safiyya Ingar (Muna in the film), writer Suhayla El-Bushra, and producer Nicky Bentham. They reflect on the inspiration behind the film, casting choices, and the emotional journey of bringing such an intense and thought-provoking story to life. Thanks to Vue Lumière for partnering with us on this episode. Become a patron of Girls On Film on Patreon here: www.patreon.com/girlsonfilmpodcast Follow us on socials: www.instagram.com/girlsonfilm_podcast/ www.facebook.com/girlsonfilmpodcast www.twitter.com/GirlsOnFilm_Pod www.twitter.com/annasmithjourno Watch Girls On Film on the BFI's YouTube channel: www.youtube.com/playlist?list=PLX…L89QKZsN5Tgr3vn7z Girls On Film is an HLA production. Host: Anna Smith Executive Producer: Hedda Lornie Archbold Producer: Negin Nia Intern: Ruby Bradshaw Audio Editor: Emma Butt Principal Partners: Vanessa Smith and Peter Brewer © HLA Agency

How is a decades-old scientific tool that revolutionized organ transplantation now being used in cancer immunotherapy and autoimmune disease?In this episode of Science with a Twist, host Terri Somers talks to experts in immunogenetics and histocompatibility about human leukocyte antigens, or HLAs, which are biomarkers on our cells that provide crucial information about our immune system. HLAs have been used for decades now to match the right donated organ or cells to a patient in need. As science has gained a deeper understanding of the immune system, the utility of HLAs has expanded significantly, helping to transform healthcare.Guests-at-a-Glance Name: Marcelo Fernandez Vina

On this episode of Girls On Film, Anna Smith speaks with the creative teams behind two strikingly different films, both exploring relationships, emotion, and identity. First, she sits down with Emma Thompson to discuss Dead of Winter, a tense new thriller directed by Brian Kirk. Thompson stars as Barb, a widow caught in a deadly snowstorm in northern Minnesota. They talk about stepping into this high-stakes role, balancing action with emotion, the challenges of filming, and the layered relationship between Barb and her late husband. Later, Anna is joined by filmmaker Sophie Dupuis to talk about her Canadian romantic drama Solo. Together, they explore the inspiration behind the story, the filmmaking process, and the themes at its core. SOLO, which is described as “a shower of glitter,” tells the story of Simon, an emerging Montreal drag queen caught between a destructive love affair and a long-awaited, complicated reunion with his mother. With the most queer cast ever assembled in a Canadian production, the film embraces queerness not as conflict, but as community, perspective, and joy. SOLO is out now in UK cinemas, go to Solofilm.co.uk for info on where to see the film whenever you are listening to this podcast DEAD OF WINTER will be released in UK and Irish cinemas from 26th September. This episode is in partnership with Peccadillo Pictures. Become a patron of Girls On Film on Patreon here: www.patreon.com/girlsonfilmpodcast Follow us on socials: www.instagram.com/girlsonfilm_podcast/ www.facebook.com/girlsonfilmpodcast www.twitter.com/GirlsOnFilm_Pod www.twitter.com/annasmithjourno Watch Girls On Film on the BFI's YouTube channel: www.youtube.com/playlist?list=PLX…L89QKZsN5Tgr3vn7z Girls On Film is an HLA production. Host: Anna Smith Executive Producer: Hedda Lornie Archbold Producer: Negin Nia Audio Editor: Elliana Jay Hamer This episode is in part-partnership with Peccadillo Pictures Principal Partners: Vanessa Smith and Peter Brewer Sponsored by Lilac Grove Entertainment © HLA Agency

For its landmark 200th episode, Girls On Film celebrates with a very special discussion on the future of film criticism and the vital role of diverse voices. The episode begins with heartfelt, celebratory words from listeners, past guests, and colleagues, reflecting on the journey of the podcast since its launch. Host Anna Smith then unveils The Critical Gap, a ground-breaking new survey commissioned by Girls On Film and conducted by Louisa Livingston and her team at Forward Thought. Inspired by the 2018 Annenberg Inclusion Initiative research that sparked the creation of this podcast, this UK-focused study surveyed over 100 critics of all genders, addressing issues of access, diversity and pay. The findings reveal stark inequalities: women film critics earn over 19% less than men—one of the worst gender pay gaps in UK culture. The report also highlights systemic barriers and ongoing challenges faced by underrepresented groups. The full report is now available on the Girls On Film website. To discuss the findings, Anna is joined by two leading voices in film criticism: Jane Crowther, Chair of the Critics' Circle Film Section, and Akua Gyamfi, founder of The British Blacklist. Together, they reflect on the survey, progress made, the spaces still needed for meaningful conversation, and the steps towards a more inclusive future for film criticism. Anna is also joined by Hanna Flint, co-founder of the LFF Critics Support Fund, the crowdfunded initiative offering financial aid to critics from low-income backgrounds so they can attend the BFI London Film Festival. Special thanks to Lilac Grove Entertainment for sponsoring this celebratory episode. Become a patron of Girls On Film on Patreon here: www.patreon.com/girlsonfilmpodcast Follow us on socials: www.instagram.com/girlsonfilm_podcast/ www.facebook.com/girlsonfilmpodcast www.twitter.com/GirlsOnFilm_Pod www.twitter.com/annasmithjourno Watch Girls On Film on the BFI's YouTube channel: www.youtube.com/playlist?list=PLX…L89QKZsN5Tgr3vn7z Girls On Film is an HLA production. Host: Anna Smith Executive Producer: Hedda Lornie Archbold Producer: Negin Nia Intern: Ruby Bradshaw Audio Editor: Emma Butt Principal Partners: Vanessa Smith and Peter Brewer © HLA Agency

Agnar Freyr Gunnarsson er gestur í Hlaðvarpinu með Óla Jóns í þriðja sinn, sem viðmælandi í apríl 2021 og gestastjórnandi í viðtali við Styrmi Másson í desember sama ár. Agnar er Head of Digital hjá Birtingahúsinu og hefur starfað í markaðsmálum síðan 2010. Þeir ræða um markaðssetningu, stafræna miðla, leitarvélabestun og hvernig fyrirtæki ættu að nálgast markaðsmál.Agnar er Head of Digital hjá Birtingahúsinu og hefur starfað í markaðsmálum síðan 2010. Þeir ræða um markaðssetningu, stafræna miðla, leitarvélabestun og hvernig fyrirtæki ættu að nálgast markaðsmál. Bakgrunnur Agnars Hefur starfað í markaðsmálum síðan 2010 Var markaðsstjóri hjá Dýrheimum í fjögur ár Starfaði hjá Vert markaðsstofu Hóf störf hjá Birtingahúsinu 1. apríl 2020 Áhugi á markaðsmálum Heillaðist af markaðsfræði strax í fyrsta áfanga í viðskiptafræði Sér markaðsfræði sem dýnamískt og skemmtilegt fag Finnst fáir dagar eins í markaðsmálum Hefur gaman af samtölum við ólíka viðskiptavini með mismunandi þarfir Þróun markaðsfræðinnar Agnar lýsir því hvernig markaðsfræðin er í stöðugri þróun. Hann nefnir að efni sem hann notaði í fyrirlestri 2021 sé að hluta til orðið úrelt vegna örar þróunar í faginu. Markaðssetning og kaupferli Agnar líkir kaupferlinu við hring frekar en trekt (funnel). Mikilvægt er að hugsa um hvað gerist eftir að viðskiptavinur kaupir Ánægðir viðskiptavinir koma aftur Agnar tekur dæmi um foreldra sína sem fóru aftur til sama fyrirtækis fyrir nýja baðherbergisinnréttingu vegna góðrar fyrri reynslu. Hvar á að byrja í markaðssetningu? Byrjum á að skoða grunninn - fjögur P-markaðsráðanna: Product (vara) Price (verð) Place (dreifing) Promotion (kynning) Mikilvægt að vita: Hvað kostar að selja vöruna? Hver er markhópurinn? Hvernig er heimasíðan? Eru upplýsingar aðgengilegar? Fyrstu krónurnar ættu að fara í keyptar leitarniðurstöður (Google Ads). Mælikvarðar í markaðssetningu Forðast „hégómamælikvarða“ (vanity metrics) eins og fjölda smella án samhengis Mikilvægt er að hafa allar upplýsingar, ekki bara hluta þeirra, til dæmis í samlíkingu við íþróttir: Að segja „ég skoraði 5 mörk“ segir lítið ef ekki er vitað hversu mörg mörk mótherjinn skoraði. Val á miðlum Prógrammatískar birtingar: Hægt er að miða nákvæmar á markhópa eftir áhugasviði, lýðfræði o.fl. Dæmi: Google Display, Meta (Facebook, Instagram) Sem dæmi nefnir Agnar að auglýsa námskeið Leitarvélaauglýsingum Prógrammatískum birtingum á viðeigandi miðlum Að skilgreina áhugasvið markhópsins YouTube-auglýsingar: Hagstætt CPM-verð Mikilvægt er að takmarka tíðni birtinga (cappa impressions). Gott er að skoða hvar auglýsingar birtast og útiloka óviðeigandi rásir. Prófanir og A/B test Agnar mælir með því að prófa mismunandi nálganir í auglýsingum. A/B test getur verið: Sama auglýsing, mismunandi hópar Sami hópur, mismunandi auglýsingar Þarf ekki að kosta mikið í birtingum Eftirfylgni og endurmat Mikilvægt er að fylgja eftir árangri markaðsaðgerða Safna endurgjöf frá viðskiptavinum Nota vitnisburði ánægðra viðskiptavina Breyta skilaboðum eftir því hvar vara er í lífsferli sínum Gervigreind og schema markup Schema markup (structured data): Kóði sem útskýrir betur fyrir leitarvélum og gervigreind hvað síðan inniheldur Hjálpar til við að fá „rich results“ í leitarniðurstöðum Verður mikilvægara með tilkomu AI overview í Google AI overview og non-click search: Google sýnir nú svör við spurningum án þess að notandi þurfi að smella á vefsíðu Getur dregið úr umferð á vefsíður Mikilvægt er að hafa vel uppsettan schema markup til að gervigreind vísi í þitt efni Að halda sér upplýstum Virkja tengslanetið og hitta fólk í faginu Think with Google og Accelerate Google LinkedIn-samfélög eins og PPC (pay-per-click) Taka frá tíma til að grúska, skoða og prófa nýja hluti

Í þætinum í dag ræða Andri og Ólafur um einn óvenjulegasta atburð Íslandssögunnar, þegar Jörgen Jörgensen (Jörundur Hundadagakonungur) rændi völdum á Íslandi sumarið 1809 og lýsti yfir ótímabæru sjálfstæði Íslands.Sagan hefur verið innblástur skálda og höfunda, og hefur einnig verið mikið um hana fjallað á hinu fræðilega sviði. Jörundur kom með enskum kaupmönnum í miðri Napóleonsstyrjöld sem vildu koma á verslun við Íslendinga. Vegna tregðu danska stiftamtansins til að veita verslunarleyfi fór svo að Jörgensen tók sér vald "Alls Íslands Verndara, og Hæstráðanda til Sjós og Lands" þar til Íslendingar myndu stofna sjálfstætt lýðveldi "laust og liðugt frá Danmerkur ríkisráðum". Hlaðvarpið Söguskoðun má nálgast hér:Soguskodun.com | soguskodun@gmail.comEinnig á Facebook og Youtube. Hægt er að styrkja hlaðvarpið með því að bjóða okkur upp á kaffibolla.

Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) CEO Phillip L'Huillier takes Proactive's Stephen Gunnion through the company's annual results and latest business update. He highlighted progress across Scancell's clinical pipeline, particularly the SCOPE study in melanoma. L'Huillier said the trial has answered four critical questions, including product selection, target patient population, administration, and dosing schedule. The company has chosen its iSCIB1+ candidate for further development, after observing “meaningful clinical benefit comes from administering our drug on top of standard of care.” He noted that the therapy is showing strong results in patients with specific HLA haplotypes, with the ability to use a screening tool to identify responders for future trials. On efficacy, L'Huillier explained: “In our combined cohort, in the target population where we've got 72 patients, we're seeing a progression-free survival of 69% at 22 months. And if you compare that to the historic standard of care, it's 11.5 months.” The CEO also discussed the Modi-1 programme in phase 2 for head and neck cancer and renal cell carcinoma, and progress on antiglycan antibodies, which are being advanced under a new subsidiary. Looking ahead, Scancell is preparing for regulatory discussions with the FDA, EMA and MHRA, while also engaging potential partners and investors. For more interviews like this, visit Proactive's YouTube channel. Don't forget to give the video a like, subscribe to the channel, and enable notifications for future content. #Scancell #CancerResearch #Biotech #Melanoma #ClinicalTrials #Immunotherapy #Pharma #Biotechnology #CancerTreatment #Oncology

Send us a textWhen rashes, hair loss, vertigo, and crushing fatigue sent Michelle to the ER (more than once), she was told it was “just stress.” The real cause? Hidden mold—from an apartment that had flooded repeatedly and an HVAC system pushing contaminated air. In this raw, practical interview, Michael Rubino unpacks Michelle's step-by-step journey: missed diagnoses, what finally revealed the problem (pro-level testing with HVAC running), why roommates can be “fine” while you're not, and how toxigenic molds like Chaetomium can impact the brain.You'll learn:Early signs Michelle missed (and why “sleeping 12 hours” didn't help)Why landlord “moisture meter checks” aren't real investigationsThe test that finally exposed the problem: air sampling with HVAC onHidden sources (under tubs, inside walls) and why baths can worsen exposureHow genetics (HLA types) and biochemistry shape symptomsWhat to ask inspectors & property managers (and when to self-test)The emotional toll: gaslighting, isolation, and staying resilient

This episode is the very first edition of MK3D recorded in Edinburgh, as part of the Edinburgh International Book Festival. Mark Kermode talks to three iconic Scottish actors: Brian Cox, whose directorial debut Glenrothan opens later this year. Kate Dickie, who is currently on Netflix in Department Q, and Michelle Gomez, BAFTA-nominated for her role as Missy in Doctor Who.Sit back and enjoy this MK3D show recorded live at McEwan Hall in Edinburgh.With thanks to Charlotte Matheson at HLA and Lilidh Kendrick and Jenny Niven and the whole, brilliant team at the Edinburgh International Book Festival.---Opening title quotes from:Mary Poppins (Robert Stevenson, Walt Disney Productions – featuring Julie Andrews)Nope (Jordan Peele, Universal Pictures – featuring Keke Palmer)Withnail & I (Bruce Robinson, HandMade Films – featuring Richard E. Grant)The Exorcist (William Friedkin, Warner Bros. – featuring Ellen Burstyn and Linda Blair)These films are essential viewing.Watch them. Love them. Share them.They are masterpieces.MK3D is an HLA Agency production© HLA Agency Hosted on Acast. See acast.com/privacy for more information.

TWiV reviews fradulent science becoming an industry, FDA may not authorize Pfizer COVID vaccine for young kids, Kennedy won't push strict pesticide regulations conserved betacoronavirus sequences recognized by human T cells, and Bispecific antibodies protect against herpes recurrent disease. Hosts: Vincent Racaniello, Alan Dove, and Brianne Barker Subscribe (free): Apple Podcasts, RSS, email Become a patron of TWiV! Links for this episode Support science education at MicrobeTV Frontiers in Comparative Systems Virology Fradulent science becomes an industry (Science) FDA may not authorize Pfizer COVID vaccine for young kids (CIDRAP) Kennedy Won't Push Strict Pesticide Regulations (NY Times) Conserved betacoronavirus sequences recognized by human T cells (Cell) Bispecific antibodies protect against herpes recurrent disease (Cell Rep) Letters read on TWiV 1245 Timestamps by Jolene Ramsey. Thanks! Weekly Picks Brianne – New Study Suggests Using AI Made Doctors Less Skilled at Spotting Cancer Alan – Save the Microbes effort gets off the ground Vincent – Dr. Vinay Prasad's Catch-22: The Only Way He Can Truly Succeed at His Job is to Get Fired Again Listener Picks Chaim – “Virus Hunters” by Greer Williams Bridget – Wave Life Sciences and their potential treatment for Alpha-1 antitrypsin deficiency Intro music is by Ronald Jenkees Send your virology questions and comments to twiv@microbe.tv Content in this podcast should not be construed as medical advice.

Host Anna Smith is joined by PAST LIVES director Celine Song to talk about her new star-studded film, MATERIALISTS. Lucy (Dakota Johnson) works as a match-maker struggling to balance financial expectations with love. Celine discusses being a feminist filmmaker, her own match-making career, and the struggle of universal loneliness. She also gives some personal advice to young women in film. Anna then speaks to Jasmin Gordon about her directorial debut THE COURAGEOUS, which follows a rebellious mother living on the edge of society who fights to keep her family together. Jasmin talks about the impact of her childhood on the film, pressure on women and mothers, and rebellion in current times. Jasmin also reveals exclusive information about her next feature film. MATERIALISTS is in UK and Irish cinemas from August 13, 2025. THE COURAGEOUS is comes to UK and Irish cinemas September 5, 2025. MOTHERBOARD releases August 15 2025. Become a patron of Girls On Film on Patreon here: www.patreon.com/girlsonfilmpodcast Follow us on socials: www.instagram.com/girlsonfilm_podcast/ www.facebook.com/girlsonfilmpodcast www.twitter.com/GirlsOnFilm_Pod www.twitter.com/annasmithjourno Watch Girls On Film on the BFI's YouTube channel: www.youtube.com/playlist?list=PLX…L89QKZsN5Tgr3vn7z Girls On Film is an HLA production. Host: Anna Smith Executive Producer: Hedda Lornie Archbold Producer: Charlotte Matheson Intern: Ruby Bradshaw Audio Editor: Emma Butt Principal Partners: Vanessa Smith and Peter Brewer © HLA Agency

Dr. Chris Wiebe shares his expertise in use of HLA eplet mismatch load in estimating immunologic risk in transplantation. We cover considerations of de novo HLA-DSA formation, donor selection, impacts on post-transplant monitoring protocols, as well as immunosuppression.

For its 198th episode, Girls On Film returns to Latitude Festival, where host Anna Smith chairs a panel with four brilliant women in film and television. This is the third live Girls On Film podcast recording from the festival, and it's absolutely fabulous! First up, Anna is joined by actor Jane Horrocks, who talks about her work on Absolutely Fabulous, on Life Is Sweet with director Mike Leigh, and on her role in Chicken Run, as well as the changes she has witnessed in the film and television industries over the course of her career. Next Anna speaks with Priya Kansara, known for her roles in Polite Society, Bridgerton, and Dope Girls, and then invites two of the driving forces behind the 2025 film Lollipop onto the stage, director Daisy-May Hudson and writer-performer Posy Sterling. Daisy-may also discusses her feature documentary Holloway. Together, the women talk about collaborating, imposter syndrome and the systemic changes they would like to see in the industry to improve access and representation for underrepresented groups. This episode was recorded at The Listening Post at Latitude Festival on Friday 25th of July 2025. Special thanks to Latitude, and to our sponsor for this episode, Lilac Grove Entertainment. Sign up to the Girls On Film newsletter here: http://eepurl.com/iEKaM-/ Or email girlsonfilmsocial@gmail.com to be signed up. Visit our new website www.girlsonfilm.org.uk Become a patron of Girls On Film on Patreon here: www.patreon.com/girlsonfilmpodcast Follow us on socials: www.instagram.com/girlsonfilm_podcast/ www.facebook.com/girlsonfilmpodcast www.twitter.com/GirlsOnFilm_Pod www.twitter.com/annasmithjourno Watch Girls On Film on the BFI's YouTube channel: www.youtube.com/playlist?list=PLX…L89QKZsN5Tgr3vn7z Girls On Film is an HLA production. Host: Anna Smith Executive Producer: Hedda Lornie Archbold Producer: Charlotte Matheson Audio Editor: Benjamin Cook Principal Partners: Vanessa Smith and Peter Brewer Sponsored by Lilac Grove Entertainment © HLA Agency

We switch from movies to the stage to talk about SING STREET: THE MUSICAL. Anna speaks with iconic producer Barbara Broccoli about her approach in adapting the film into a stage show. Barbara came on our 100th episode of Girls On Film to talk about her work, the Time's Up movement, and No Time To Die. As well as producing the Bond films at Eon Productions, she has produced female-led movies such as Film Stars Don't Die In Liverpool, Nancy, Till, and Blue Road: The Edna O'Brien Story. Anna also chats with the show's director, Rebecca Taichman, about approaching the correct tone and staging for the show. Rebecca is one of only six women to win the TONY Award for Best Direction of a Play, which she took home in 2017 for "INDECENT," by Paula Vogel. With a diverse repertoire spanning Shakespeare, contemporary plays, opera, and musicals, Taichman is a visionary director who enjoys conceiving of and co-creating new work. We're also joined by John Carney who is known for music-led films such as Once and Begin Again, and who directed and co-wrote the original feature film Sing Street. SING STREET: THE MUSICAL is running from July 8 - August 23 2025 at the Hammersmith Theatre, London. Check out the website for more details: https://lyric.co.uk/shows/sing-street/ . Sign up to the Girls On Film newsletter here: http://eepurl.com/iEKaM-/ . Or email girlsonfilmsocial@gmail.com to be signed up. Visit our new website www.girlsonfilm.org.uk Become a patron of Girls On Film on Patreon here:www.patreon.com/girlsonfilmpodcast Follow us on socials: www.instagram.com/girlsonfilm_podcast / www.facebook.com/ girlsonfilmpodcast / https://bsky.app/profile/girlsonfilmpodcast.bsky.social https://bsky.app/profile/annasmithjourno.bsky.social Watch Girls On Film on the BFl's YouTube channel: www.youtube.com/playlist?list=PLX...L89QKZsN5Tgr3vn7z Girls On Film is an HLA production. Host: Anna Smith Executive Producer: Hedda Lornie Archbold Producer: Charlotte Matheson Audio Editor: Emma Butt. This episode is supported by Lilac Grove Entertainment. Principal Partners: Vanessa Smith and Peter Brewer © HLA Agency

Í framhaldi af síðasta þætti um írönsku byltinguna ræða Andri og Ólafur í dag eitt af mannskæðustu stríðum 20. aldarinnar – stríðið milli Írans og Íraks 1980–1988.Saddam Hussein hóf forsetatíð sína í Írak með því að ráðast inn í Íran haustið 1980 í kjölfar írönsku byltingarinnar og þeirrar upplausnar sem þá ríkti í landinu. Stríðið stóð í átta ár og kostaði hundruð þúsunda mannslífa. Það var háð sem hefðbundið innrásarstríð með stórútgerðum í lofti, á láði og legi, þar sem vopn frá báðum hliðum járntjaldsins flæddu inn á vígvöllinn. Með tímanum harðnaði hernaðurinn, og meðal annars var beitt efnavopnum, barnahermenn sendir í fremstu víglínu og möguleg kjarnavopn komu við sögu.Þótt Saddam næði engum varanlegum landvinningum og landamæri ríkjanna héldust óbreytt hafði stríðið djúp áhrif. Það styrkti íranska byltingarríkið og festi stjórn Khomeini í sessi og Saddam kom fram sem stríðsherra sem veigraði sér ekki við að beita gjöreyðingarvopnum, og það hafði afleiðingar sem við þekkjum vel í nýlegri fortíð.Hlaðvarpið Söguskoðun má nálgast hér:Soguskodun.com | soguskodun@gmail.comEinnig á Facebook og Youtube. Hægt er að styrkja hlaðvarpið með því að bjóða okkur upp á kaffibolla.

In this episode of Hanselminutes, Scott Hanselman talks with Randall Hyde, renowned for his expertise in programming and assembly language. Known as the creator of the Lisa Assembler and the author of The Art of Assembly Language and Write Great Code series, Randall shares his journey from developing in assembler for early computing systems to working on modern nuclear reactor control systems. He discusses the evolution of software development, the value of assembly language in today's programming landscape, teaching methodologies, and the balance between low-level understanding and high-level productivity.Key TopicsRandall Hyde's Academic and Professional Background (00:02.72)Assembly Language Beginnings with the Lisa Assembler (00:33.45)The Evolution of Randall's Work from Games to Nuclear Engineering (04:54.99)The Importance of Understanding Low-Level Machine Behavior (06:46.75)How Assembly Language Has Evolved and Its Modern Relevance (16:11.62)HLA (High-Level Assembler) as a Teaching Tool (20:20.46)The Rise of ARM Architectures and Changing Processor Technology (29:24.59)The Need for Efficient Code in the Multi-Core Era (33:31.42)Main TakeawaysLow-Level Understanding is Foundational: Randall emphasizes that understanding machine organization and low-level behavior is essential to writing better high-level code.Practical vs. Academic Learning: College enforces learning through structure, but much of coding excellence comes from individual, rigorous practice in understanding how systems work under the hood.Evolving Utility of Assembly Language: While assembly language isn't a daily tool for most programmers, knowing it provides critical insights into low-level optimizations essential for performance-critical applications.Shift in Performance Gains: Modern compilers and multi-core systems have reduced the performance advantages of assembly, yet efficient code writing remains vital as architecture advances slow down.Accessible Education: Randall's approach – from pioneering HLA as a bridge to assembly to his comprehensive Write Great Code series – has focused on making low-level concepts easier for new learners to grasp.Resources MentionedThe Art of Assembly Language by Randall HydeWrite Great Code Series (Volumes 1-4) by Randall HydeVolume 2: Thinking Low-Level, Writing High-LevelRANDALLHYDE.COM: Hyde's website for books, support materials, and resourcesNo Starch Press (Publisher): NoStarch.comFollow along for more insights, tips, and conversations with industry leaders. These show notes summarize key moments in the podcast for easy reference and understanding - these show notes were generated by a custom gpt-4o-nano model trained in previous episodes of Hanselminutes

Í hlaðvarpinu í dag ræða Ólafur og Andri um írönsku byltinguna árið 1979, þegar síðasti keisari Írans (sha) var steypt af stóli og stofnað var róttækt íslamskt lýðveldi undir klerkastjórn.Íranska byltingin var gífurlega afdrifaríkur atburður í nútímasögu Mið-Austurlanda. Ekki aðeins varð byltingin til þess að 2500 ára gömul stofnun íranska keisarans leið undir lok, heldur breyttist Íran á skömmum tíma úr einum helsta bandamanni Bandaríkjanna í Mið-Austurlöndum, í miðju Kalda stríðinu, yfir í mesta andstæðing Bandaríkjanna og vestrænnar heimsvaldastefnu á svæðinu. Byltingin sýndi einnig að pólitískt íslam og íslamismi breyddist um svæðið og hefur heldur betur sett svip sinn á Mið-Austurlönd síðustu áratugi. Keisarastjórn Mohammad Reza Pahlavi, frá því einræði hans var komið á eftir valdarán stutt af Vesturveldunum árið 1953, varð þekkt fyrir pólitíska kúgun og persónudýrkun, en einnig mikla tækni- menningarbyltingu í krafti gríðarlegs olíuauðs. Byltingin var sannkölluð fjöldahreyfing, ein sú vinsælasta í sögunni, en byltingarríkið undir stjórn Ayatollah Khomeini var einnig harðvíðtug og Hlaðvarpið Söguskoðun má nálgast hér:Soguskodun.com | soguskodun@gmail.comEinnig á Facebook og Youtube. Hægt er að styrkja hlaðvarpið með því að bjóða okkur upp á kaffibolla.

Nesta aula, vamos desvendar as Síndromes Poliglandulares Autoimunes (SPA). Abordaremos a classificação completa, detalhando as características da SPA Tipo 1 (ligada ao gene AIRE), da SPA Tipo 2 (a mais comum, associada ao HLA) e de suas variantes. Endocrinologia descomplicada para médicos e residentes.Aqui você encontra conteúdos sobre atualização médica, casos clínicos e preparação para provas de título.

Host Anna Smith brings you a special episode of Girls On Film from the Mediterrane Film Festival in Malta, which this year celebrates 100 years of movie-making on the island. From Malta, Anna speaks with producer Susan Simnett, known for Brides, Chuck Chuck Baby, and Fadhia's Tree. She also chats to Euphoria star Barbie Ferreira, who received this year's Rising Star Award, and BAFTA-winning actor Monica Dolan, who presented at the festival's Golden Bee Awards. Back in the UK, broadcaster, film, TV and culture critic Ashanti Omkar joins Anna to discuss three powerful new films: Daisy-May Hudson and Sophie Compton's documentary Holloway, Athina Rachel Tsangari's medieval drama Harvest, and Claude Barras's stop-motion animation Savages. Harvest will be coming to UK cinemas on 18 July 2025. Keep an eye out for upcoming screenings of Holloway with Reclaim the Frame - championing intersectional feminist cinema across the UK. Check out their website for more details Savages will be released in the UK and Ireland on 1 August 2025. Find out more about the Mediterrane Film Festival on their website https://mediterrane.com/ Sign up to the Girls On Film newsletter here: http://eepurl.com/iEKaM-/ Or email girlsonfilmsocial@gmail.com to be signed up. Visit our new website www.girlsonfilm.org.uk Become a patron of Girls On Film on Patreon here: www.patreon.com/girlsonfilmpodcast Follow us on socials: www.instagram.com/girlsonfilm_podcast/ www.facebook.com/girlsonfilmpodcast www.twitter.com/GirlsOnFilm_Pod www.twitter.com/annasmithjourno Watch Girls On Film on the BFI's YouTube channel: www.youtube.com/playlist?list=PLX…L89QKZsN5Tgr3vn7z Girls On Film is an HLA production. Host: Anna Smith Executive Producer: Hedda Lornie Archbold Producer: Charlotte Matheson Audio Editor: Cam Griffiths Principal Partners: Vanessa Smith and Peter Brewer © HLA Agency

Whether you work in an HLA lab or rely on one for clinical services or care, you won't want to miss this episode of Coffee & Compatibility! James Robinson, founder of the bioinformation IPD-IMGT/HLA Database, joins us to share how this essential tool evolved into a global resource with over 74,000 submissions, 42,000+ alleles, and nearly 20 new entries every day!

Dr. Diwakar Davar and Dr. Jason Luke discuss novel agents in melanoma and other promising new data in the field of immunotherapy that were presented at the 2025 ASCO Annual Meeting. TRANSCRIPT Dr. Diwakar Davar: Hello. My name is Diwakar Davar, and I am welcoming you to the ASCO Daily News Podcast. I'm an associate professor of medicine and the clinical director of the Melanoma and Skin Cancer Program at the University of Pittsburgh's Hillman Cancer Center. Today, I'm joined by my colleague and good friend, Dr. Jason Luke. Dr. Luke is a professor of medicine. He is also the associate director of clinical research and the director of the Phase 1 IDDC Program at the University of Pittsburgh's Hillman Cancer Center. He and I are going to be discussing some key advancements in melanoma and skin cancers that were presented at the 2025 ASCO Annual Meeting. Our full disclosures are available in the transcript of this episode.  Jason, it is great to have you back on the podcast. Dr. Jason Luke: Thanks again so much for the opportunity, and I'm really looking forward to it. Dr. Diwakar Davar: Perfect. So we will go ahead and start talking a little bit about a couple of key abstracts in both the drug development immunotherapy space and the melanoma space. The first couple of abstracts, the first two, will cover melanoma. So, the first is LBA9500, which was essentially the primary results of RELATIVITY-098. RELATIVITY-098 was a phase 3 trial that compared nivolumab plus relatlimab in a fixed-dose combination against nivolumab alone for the adjuvant treatment of resected high-risk disease. Jason, do you want to maybe give us a brief context of what this is? Dr. Jason Luke: Yeah, it's great, thanks. So as almost all listeners, of course, will be aware, the use of anti–PD-1 immunotherapies really revolutionized melanoma oncology over the last 10 to 15 years. And it has become a standard of care in the adjuvant setting as well. But to review, in patients with stage III melanoma, treatment can be targeted towards BRAF with BRAF and MEK combination therapy, where that's relevant, or anti–PD-1 with nivolumab or pembrolizumab are a standard of care. And more recently, we've had the development of neoadjuvant approaches for palpable stage III disease. And in that space, if patients present, based on two different studies, either pembrolizumab or nivolumab plus ipilimumab can be given prior to surgery for somewhere in the 6- to 9-week range. And so all of these therapies have improved time-to-event endpoints, such as relapse-free or event-free survival. It's worth noting, however, that despite those advances, we've had a couple different trials now that have actually failed in this adjuvant setting, most high profile being the CheckMate-915 study, which looked at nivolumab plus ipilimumab and unfortunately was a negative study. So, with RELATIVITY-047, which was the trial of nivolumab plus relatlimab that showed an improvement in progression-free survival for metastatic disease, there's a lot of interest, and we've been awaiting these data for a long time for RELATIVITY-098, which, of course, is this adjuvant trial of LAG-3 blockade with relatlimab plus nivolumab. Dr. Diwakar Davar: Great. So with that, let's briefly discuss the trial design and the results. So this was a randomized, phase 3, blinded study, so double-blinded, so neither the investigators knew what the patients were getting, nor did the patients know what they were getting. The treatment investigational arm was nivolumab plus relatlimab in the fixed-dose combination. So that's the nivolumab standard fixed dose with relatlimab that was FDA approved in RELATIVITY-047. And the control arm was nivolumab by itself. The duration of treatment was 1 year. The patient population consisted of resected high-risk stage III or IV patients. The primary endpoint was investigator-assessed RFS. Stage and geography were the standard stratifying factors, and they were included, and most of the criteria were balanced across both arms. What we know at this point is that the 2-year RFS rate was 64% and 62% in the nivolumab and nivolumab-combination arms, respectively. The 2-year DMFS rate was similarly equivalent: 76% with nivolumab monotherapy, 73% with the combination. And similar to what you had talked about with CheckMate 915, unfortunately, the addition of LAG-3 did not appear to improve the RFS or DMFS compared to control in this patient population. So, tell us a little bit about your take on this and what do you think might be the reasons why this trial was negative? Dr. Jason Luke: It's really unfortunate that we have this negative phase 3 trial. There had been a lot of hope that the combination of nivolumab with relatlimab would be a better tolerated combination that increased the efficacy. So in the metastatic setting, we do have 047, the study that demonstrated nivolumab plus relatlimab, but now we have this negative trial in the adjuvant setting. And so as to why exactly, I think is a complicated scenario. You know, when we look at the hazard ratios for relapse-free survival, the primary endpoint, as well as the secondary endpoints for distant metastasis-free survival, we see that the hazard ratio is approximately 1. So there's basically no difference. And that really suggests that relatlimab in this setting had no impact whatsoever on therapeutic outcomes in terms of efficacy. Now, it's worth noting that there was a biomarker subanalysis that was presented in conjunction with these data that looked at some immunophenotyping, both from circulating T cells, CD8 T cells, as well as from the tumor microenvironment from patients who were treated, both in the previous metastatic trial, the RELATIVITY-047 study, and now in this adjuvant study in the RELATIVITY-098 study. And to briefly summarize those, what was identified was that T cells in advanced melanoma seemed to have higher expression levels of LAG-3 relative to T cells that are circulating in patients that are in the adjuvant setting. In addition to that, there was a suggestion that the magnitude of increase is greater in the advanced setting versus adjuvant. And the overall summary of this is that the suggested rationale for why this was a negative trial may have been that the target of LAG-3 is not expressed as highly in the adjuvant setting as it is in the metastatic setting. And so while the data that were presented, I think, support this kind of an idea, I am a little bit cautious that this is actually the reason for why the trial was negative, however. I would say we're not really sure yet as to why the trial was negative, but the fact that the hazard ratios for the major endpoints were essentially 1 suggests that there was no impact whatsoever from relatlimab. And this really makes one wonder whether or not building on anti–PD-1 in the adjuvant setting is feasible because anti–PD-1 works so well. You would think that even if the levels of LAG-3 expression were slightly different, you would have seen a trend in one direction or another by adding a second drug, relatlimab, in this scenario. So overall, I think it's an unfortunate circumstance that the trial is negative. Clearly there's going to be no role for relatlimab in the adjuvant setting. I think this really makes one wonder about the utility of LAG-3 blockade and how powerful it really can be. I think it's probably worth pointing out there's another adjuvant trial ongoing now of a different PD-1 and LAG-3 combination, and that's cemiplimab plus fianlimab, a LAG-3 antibody that's being dosed from another trial sponsor at a much higher dose, and perhaps that may make some level of difference. But certainly, these are unfortunate results that will not advance the field beyond where we were at already. Dr. Diwakar Davar: And to your point about third-generation checkpoint factors that were negative, I guess it's probably worth noting that a trial that you were involved with, KeyVibe-010, that evaluated the PD-1 TIGIT co-formulation of vibostolimab, MK-4280A, was also, unfortunately, similarly negative. So, to your point, it's not clear that all these third-generation receptors are necessarily going to have the same impact in the adjuvant setting, even if they, you know, for example, like TIGIT, and they sometimes may not even have an effect at all in the advanced cancer setting. So, we'll see what the HARMONY phase 3 trial, that's the Regeneron cemiplimab/fianlimab versus pembrolizumab control with cemiplimab with fianlimab at two different doses, we'll see how that reads out. But certainly, as you've said, LAG-3 does not, unfortunately, appear to have an impact in the adjuvant setting. So let's move on to LBA9501. This is the primary analysis of EORTC-2139-MG or the Columbus-AD trial. This was a randomized trial of encorafenib and binimetinib, which we will abbreviate as enco-bini going forward, compared to placebo in high-risk stage II setting in melanoma in patients with BRAF V600E or K mutant disease. So Jason, you know, you happen to know one or two things about the resected stage II setting, so maybe contextualize the stage II setting for us based on the trials that you've led, KEYNOTE-716, as well as CheckMate-76K, set us up to talk about Columbus-AD. Dr. Jason Luke: Thanks for that introduction, and certainly stage II disease has been something I've worked a lot on. The rationale for that has been that building off of the activity of anti–PD-1 in metastatic melanoma and then seeing the activity in stage III, like we just talked about, it was a curious circumstance that dating back about 7 to 8 years ago, there was no availability to use anti–PD-1 for high-risk stage II patients, even though the risk of recurrence and death from melanoma in the context of stage IIB and IIC melanoma is in fact similar or actually higher than in stage IIIA or IIIB, where anti–PD-1 was approved. And in that context, a couple of different trials that you alluded to, the Keynote-716 study that I led, as well as the CheckMate 76K trial, evaluated pembrolizumab and nivolumab, respectively, showing an improvement in relapse-free and distant metastasis-free survival, and both of those agents have subsequently been approved for use in the adjuvant setting by the US FDA as well as the European Medicines Agency.  So bringing then to this abstract, throughout melanoma oncology, we've seen that the impact of anti–PD-1 immunotherapy versus BRAF and MEK-targeted therapy have had very similar outcomes on a sort of comparison basis, both in frontline metastatic and then in adjuvant setting. So it was a totally reasonable question to ask: Could we use adjuvant BRAF and MEK inhibitor therapy? And I think all of us expected the answer would be yes. As we get into the discussion of the trial, I think the unfortunate circumstance was that the timing of this clinical trial being delayed somewhat, unfortunately, made it very difficult to accrue the trial, and so we're going to have to try to read through the tea leaves sort of, based on only a partially complete data set. Dr. Diwakar Davar: So, in terms of the results, they wanted to enroll 815 patients, they only enrolled 110. The RFS and DMFS were marginally improved in the treatment arm but certainly not significantly, which is not surprising because the trial had only accrued 16% to 18% of its complete accrual. As such, we really can't abstract from the stage III COMBI-AD data to stage II patients. And certainly in this setting, one would argue that the primary treatment options certainly remain either anti–PD-1 monotherapy, either with pembrolizumab or nivolumab, based on 716 or 76K, or potentially active surveillance for the patients who are not inclined to get treated.  Can you tell us a little bit about how you foresee drug development going forward in this space because, you know, for example, with HARMONY, certainly IIC disease is a part of HARMONY. We will know at least a little bit about that in this space. So what do you think about the stage IIB/C patient population? Is this a patient population in which future combinations are going to be helpful, and how would you think about where we can go forward from here? Dr. Jason Luke: It is an unfortunate circumstance that this trial could not be accrued at the pace that was necessary. I think all of us believe that the results would have been positive if they'd been able to accrue the trial. In the preliminary data set that they did disclose of that 110 patients, you know, it's clear there is a difference at a, you know, a landmark at a year. They showed a 16% difference, and that would be in line with what has been seen in stage III. And so, you know, I think it's really kind of too bad. There's really going to be no regulatory approach for this consideration. So using BRAF and MEK inhibition in stage II is not going to be part of standard practice moving into the future. To your point, though, about where will the field go? I think what we're already realizing is that in the adjuvant setting, we're really overtreating the total population. And so beyond merely staging by AJCC criteria, we need to move to biomarker selection to help inform which patients truly need the treatment. And in that regard, I don't think we've crystallized together as a field as yet, but the kinds of things that people are thinking about are the integration of molecular biomarkers like ctDNA. When it's positive, it can be very helpful, but in melanoma, we found that, unfortunately, the rates are quite low, you know, in the 10% to 15% range in the adjuvant setting. So then another consideration would be factors in the primary tumor, such as gene expression profiling or other considerations.  And so I think the future of adjuvant clinical trials will be an integration of both the standard AJCC staging system as well as some kind of overlaid molecular biomarker that helps to enrich for a higher-risk population of patients because on a high level, when you abstract out, it's just clearly the case that we're rather substantially overtreating the totality of the population, especially given that in all of our adjuvant studies to date for anti–PD-1, we have not yet shown that there's an overall survival advantage. And so some are even arguing perhaps we should even reserve treatment until patients progress. I think that's a complicated subject, and standard of care at this point is to offer adjuvant therapy, but certainly a lot more to do because many patients, you know, unfortunately, still do progress and move on to metastatic disease. Dr. Diwakar Davar: Let's transition to Abstract 2508. So we're moving on from the melanoma to the novel immunotherapy abstracts. And this is a very, very, very fascinating drug. It's IMA203. So Abstract 2508 is a phase 1 clinical update of IMA203. IMA203 is an autologous TCR-T construct targeting PRAME in patients with heavily pretreated PD-1-refractory metastatic melanoma. So Jason, in the PD-1 and CTLA-4-refractory settings, treatment options are either autologous TIL, response rate, you know, ballpark 29% to 31%, oncolytic viral therapy, RP1 with nivolumab, ORR about 30-ish percent. So new options are needed. Can you tell us a little bit about IMA203? Perhaps tell us for the audience, what is the difference between a TCR-T and traditional autologous TIL? And a little bit about this drug, IMA203, and how it distinguishes itself from the competing TIL products in the landscape. Dr. Jason Luke: I'm extremely enthusiastic about IMA203. I think that it really has transformative potential based on these results and hopefully from the phase 3 trial that's open to accrual now. So, what is IMA203? We said it's a TCR-T cell product. So what that means is that T cells are removed from a patient, and then they can be transduced through various technologies, but inserted into those T cells, we can then add a T-cell receptor that's very specific to a single antigen, and in this case, it's PRAME. So that then is contrasted quite a bit from the TIL process, which includes a surgical resection of a tumor where T cells are removed, but they're not specific necessarily to the cancer, and they're grown up in the lab and then given to the patient. They're both adoptive cell transfer products, but they're very different. One is genetically modified, and the other one is not. And so the process for generating a TCR-T cell is that patients are required to have a new biomarker that some may not be familiar with, which is HLA profiling. So the T-cell receptor requires matching to the concomitant HLA for which the peptide is bound in. And so the classic one that is used in most oncology practices is A*02:01 because approximately 48% of Caucasians have A*02:01, and the frequency of HLA in other ethnicities starts to become highly variable. But in patients who are identified to have A*02:01 genotype, we can then remove blood via leukapheresis or an apheresis product, and then insert via lentiviral transduction this T-cell receptor targeting PRAME. Patients are then brought back to the hospital where they can receive lymphodepleting chemotherapy and then receive the reinfusion of the TCR-T cells. Again, in contrast with the TIL process, however, these T cells are extremely potent, and we do not need to give high-dose interleukin-2, which is administered in the context of TIL. Given that process, we have this clinical trial in front of us now, and at ASCO, the update was from the phase 1 study, which was looking at IMA203 in an efficacy population of melanoma patients who were refractory at checkpoint blockade and actually multiple lines of therapy. So here, there were 33 patients and a response rate of approximately 50% was observed in this population of patients, notably with a duration of response approximately a year in that treatment group. And I realize that these were heavily pretreated patients who had a range of very high-risk features. And approximately half the population had uveal melanoma, which people may be aware is a generally speaking more difficult-to-treat subtype of melanoma that metastasizes to the liver, which again has been a site of resistance to cancer immunotherapy. So these results are extremely promising. To summarize them from what I said, it's easier to make TCR-T cells because we can remove blood from the patient to transduce the T cells, and we don't have to put them through surgery. We can then infuse them, and based on these results, it looks like the response rate to IMA203 is a little bit more than double what we expect from lifileucel. And then, whereas with lifileucel or TILs, we have to give high-dose IL-2, here we do not have to give high-dose IL-2. And so that's pretty promising. And a clinical trial is ongoing now called the SUPREME phase 3 clinical trial, which is hoping to validate these results in a randomized global study. Dr. Diwakar Davar: Now, one thing that I wanted to go over with you, because you know this trial particularly well, is what you think of the likelihood of success, and then we'll talk a little bit about the trial design. But in your mind, do you think that this is a trial that has got a reasonable likelihood of success, maybe even a high likelihood of success? And maybe let's contextualize that to say an alternative trial, such as, for example, the TebeAM trial, which is essentially a T-cell bispecific targeting GP100. It's being compared against SOC, investigator's choice control, also in a similarly heavily pretreated patient population. Dr. Jason Luke: So both trials, I think, have a strong chance of success. They are very different kinds of agents. And so the CD3 bispecific that you referred to, tebentafusp, likely has an effect of delaying progression, which in patients with advanced disease could have a value that might manifest as overall survival. With TCR-T cells, by contrast, we see a very high response rate with some of the patients going into very durable long-term benefit. And so I do think that the SUPREME clinical trial has a very high chance of success. It will be the first clinical trial in solid tumor oncology randomizing patients to receive a cell therapy as compared with a standard of care. And within that standard of care control arm, TILs are allowed as a treatment. And so it will also be the first study that will compare TCR-T cells against TILs in a randomized phase 3. But going back to the data that we've seen in the phase 1 trial, what we observe is that the duration of response is really connected to the quality of the response, meaning if you have more than a 50% tumor shrinkage, those patients do very, very well. But even in patients who have less than 50% tumor shrinkage, the median progression-free survival right now is about 4.5 months. And again, as we think about trial design, standard of care options for patients who are in this situation are unfortunately very bad. And the progression-free survival in that population is probably more like 2 months. So this is a trial that has a very high likelihood of being positive because the possibility of long-term response is there, but even for patients who don't get a durable response, they're likely going to benefit more than they would have based on standard chemotherapy or retreatment with an anti–PD-1 agent. Dr. Diwakar Davar: Really, a very important trial to enroll, a trial that is first in many ways. First of a new generation of TCR-T agents, first trial to look at cell therapy in the control arm, a new standard of efficacy, but potentially also if this trial is successful, it will also be a new standard of trial conduct, a new kind of trial, of a set of trials that will be done in the second-line immunotherapy-refractory space. So let's pivot to the last trial that we were going to discuss, which was Abstract 2501. Abstract 2501 is a first-in-human phase 1/2 trial evaluating BNT142, which is the first-in-class mRNA-encoded bispecific targeting Claudin-6 and CD3 in patients with Claudin-positive tumors. We'll talk a little bit about this, but maybe let's start by talking a little bit about Claudin-6. So Claudin-6 is a very interesting new target. It's a target that's highly expressed in GI and ovarian tumors. There are a whole plethora of Claudin-6-targeting agents, including T-cell bispecifics and Claudin-6-directed CAR-Ts that are being developed. But BNT142 is novel. It's a novel lipid nanoparticle LNP-encapsulated mRNA. The mRNA encodes an anti–Claudin-6 CD3 bispecific termed RiboMAB-021. And it then is administered to the patient. The BNT142-encoding mRNA LNPs are taken up by the liver and translated into the active drug. So Jason, tell us a little bit about this agent. Why you think it's novel, if you think it's novel, and let's talk a little bit then about the results. Dr. Jason Luke: So I certainly think this is a novel agent, and I think this is just the first of what will probably become a new paradigm in oncology drug development. And so you alluded to this, but just to rehash it quickly, the drug is encoded as genetic information that's placed in the lipid nanoparticle and then is infused into the patient. And after the lipid nanoparticles are taken up by the liver, which is the most common place that LNPs are usually taken up, that genetic material in the mRNA starts to be translated into the actual protein, and that protein is the drug. So this is in vivo generation, so the patient is making their own drug inside their body. I think it's a really, really interesting approach. So for any drug that could be encoded as a genetic sequence, and in this case, it's a bispecific, as you mentioned, CD3-Claudin-6 engager, this could have a tremendous impact on how we think about pharmacology and novel drug development moving into the future in oncology. So I think it's an extremely interesting drug, the like of which we'll probably see only more moving forward. Dr. Diwakar Davar: Let's maybe briefly talk about the results. You know, the patient population was heavily pretreated, 65 or so patients, mostly ovarian cancer. Two-thirds of the patients were ovarian cancer, the rest were germ cell and lung cancer patients. But let's talk a little bit about the efficacy. The disease control rate was about 58% in the phase 1 population as a whole, but 75% in the ovarian patient population. Now tell us a little bit about the interesting things about the drug in terms of the pharmacokinetics, and also then maybe we can pivot to the clinical activity by dose level. Dr. Jason Luke: Well, so they did present in their presentation at ASCO a proportionality showing that as higher doses were administered, that greater amounts of the drug were being made inside the patient. And so that's an interesting observation, and it's an important one, right? Suggesting that the pharmacology that we classically think of by administering drugs by IV, for example, would still be in play. And that did translate into some level of efficacy, particularly at the higher dose levels. Now, the caveat that I'll make a note of is that disease control rate is an endpoint that I think we have to be careful about because what that really means is sometimes a little bit unclear. Sometimes patients have slowly growing tumors and so on and so forth. And the clinical relevance of disease control, if it doesn't last at least 6 months, I think is probably pretty questionable. So I think these are extremely interesting data, and there's some preliminary sense that getting the dose up is going to matter because the treatment responses were mostly observed at the highest dose levels. There's also a caveat, however, that across the field of CD3 bispecific molecules like this, there's been quite a bit of heterogeneity in terms of the response rate, with some of them only really generating stable disease responses and other ones having more robust responses. And so I think this is a really interesting initial foray into this space. My best understanding is this molecule is not moving forward further after this, but I think that this really does set it up to be able to chase after multiple different drug targets on a CD3 bispecific backbone, both in ovarian cancer, but then basically across all of oncology. Dr. Diwakar Davar: Perfect. This is a very new sort of exciting arena where we're going to be looking at, in many ways, these programmable constructs, whether we're looking at in vivo-generated, in this case, a T-cell bispecific, but we've also got newer drugs where we are essentially giving drugs where people are generating in vivo CAR T, and also potentially even in vivo TCR-T. But certainly lots of new excitement around this entire class of drugs. And so, what we'd like to do at this point in time is switch to essentially the fact that we've got a very, very exciting set of data at ASCO 2025. You've heard from Dr. Luke regarding the advances in both early drug development but also in advanced cutaneous melanoma. And Jason, as always, thank you so much for sharing your very valuable and great, fantastic insights with us on the ASCO Daily News Podcast. Dr. Jason Luke: Well, thanks again for the opportunity. Dr. Diwakar Davar: And thank you to our listeners for taking your time to listen today. You will find the links to the abstracts that we discussed today in the transcript of this episode. And finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:    Dr. Diwakar Davar    @diwakardavar    Dr. Jason Luke @jasonlukemd Follow ASCO on social media:     @ASCO on Twitter       ASCO on Bluesky   ASCO on Facebook       ASCO on LinkedIn   Disclosures:     Dr. Diwakar Davar:      Honoraria: Merck, Tesaro, Array BioPharma, Immunocore, Instil Bio, Vedanta Biosciences     Consulting or Advisory Role: Instil Bio, Vedanta Biosciences     Consulting or Advisory Role (Immediate family member): Shionogi     Research Funding: Merck, Checkmate Pharmaceuticals, CellSight Technologies, GSK, Merck, Arvus Biosciences, Arcus Biosciences     Research Funding (Inst.): Zucero Therapeutics     Patents, Royalties, Other Intellectual Property: Application No.: 63/124,231 Title: COMPOSITIONS AND METHODS FOR TREATING CANCER Applicant: University of Pittsburgh–Of the Commonwealth System of Higher Education Inventors: Diwakar Davar Filing Date: December 11, 2020 Country: United States MCC Reference: 10504-059PV1 Your Reference: 05545; and Application No.: 63/208,719 Enteric Microbiotype Signatures of Immune-related Adverse Events and Response in Relation to Anti-PD-1 Immunotherapy     Dr. Jason Luke:     Stock and Other Ownership Interests: Actym Therapeutics, Mavu Pharmaceutical, Pyxis, Alphamab Oncology, Tempest Therapeutics, Kanaph Therapeutics, Onc.AI, Arch Oncology, Stipe, NeoTX     Consulting or Advisory Role: Bristol-Myers Squibb, Merck, EMD Serono, Novartis, 7 Hills Pharma, Janssen, Reflexion Medical, Tempest Therapeutics, Alphamab Oncology, Spring Bank, Abbvie, Astellas Pharma, Bayer, Incyte, Mersana, Partner Therapeutics, Synlogic, Eisai, Werewolf, Ribon Therapeutics, Checkmate Pharmaceuticals, CStone Pharmaceuticals, Nektar, Regeneron, Rubius, Tesaro, Xilio, Xencor, Alnylam, Crown Bioscience, Flame Biosciences, Genentech, Kadmon, KSQ Therapeutics, Immunocore, Inzen, Pfizer, Silicon Therapeutics, TRex Bio, Bright Peak, Onc.AI, STipe, Codiak Biosciences, Day One Therapeutics, Endeavor, Gilead Sciences, Hotspot Therapeutics, SERVIER, STINGthera, Synthekine     Research Funding (Inst.): Merck , Bristol-Myers Squibb, Incyte, Corvus Pharmaceuticals, Abbvie, Macrogenics, Xencor, Array BioPharma, Agios, Astellas Pharma , EMD Serono, Immatics, Kadmon, Moderna Therapeutics, Nektar, Spring bank, Trishula, KAHR Medical, Fstar, Genmab, Ikena Oncology, Numab, Replimmune, Rubius Therapeutics, Synlogic, Takeda, Tizona Therapeutics, Inc., BioNTech AG, Scholar Rock, Next Cure     Patents, Royalties, Other Intellectual Property: Serial #15/612,657 (Cancer Immunotherapy), and Serial #PCT/US18/36052 (Microbiome Biomarkers for Anti-PD-1/PD-L1 Responsiveness: Diagnostic, Prognostic and Therapeutic Uses Thereof)     Travel, Accommodations, Expenses: Bristol-Myers Squibb, Array BioPharma, EMD Serono, Janssen, Merck, Novartis, Reflexion Medical, Mersana, Pyxis, Xilio

We're back in the French Riviera for a very special episode, as Girls On Film returns to the 78th edition of the Cannes Film Festival. This year, host Anna Smith welcomed guests to the second Girls On Film Cannes Do at The Members Club. This glamorous networking event on the beach brought together filmmakers, critics, and creatives celebrating the power of women in cinema. In this episode, you'll hear reflections from our community on what Girls On Film means to them. Later on in the episode Anna reunites with film journalist Wendy Ide who reflects on this year's films, which she says have been of a consistently high standard. Wendy shares her standout picks from the festival, from the fiercely divisive Die, My Love, a visceral exploration of the raw edges of motherhood and mental unravelling, to Sound of Falling, a haunting meditation on how trauma echoes through time and place. She also dives into Sirât, an allegorical road movie, in which gender and disability are refreshingly incidental, not defining. Plus other titles that are already generating serious awards buzz. And finally, we're joined by Liza van der Smissen and Nicole Lieberman, founders of the Female Film Club. This trailblazing global network uplifts women in the industry through practical workshops, seminars and a thriving, supportive community. They share the story behind their mission and how they're helping to reshape the future of film, one powerful connection at a time. They also unveil an exciting new opportunity: a £10,000 investment in a short film, designed to give back to their talented global community. To enter from 16th June onwards, filmmakers must join their networking space. If you're looking to join a space that champions and supports women in film, don't miss out – click this link to join the Female Film Club: [link: https://female-film-club.mn.co/users/onboarding/choose_plan?plan_id=1818474&bundle_token=aca8b4a8f139016aca1a9fdc680a97a8&utm_source=manual] We would also like to thank our incredible sponsors for all their support: Col Needham and Karen Needham at IMDb: [link: https://www.imdb.com/title/tt18211920/?ref_=nv_sr_srsg_3_tt_8_nm_0_in_0_q_girls%2520on%2520film] Clare Bateman-King at Lilac Grove Entertainment: [https://lilacgrove.com/] JoJo Dye at JJD Consultancy: [link: https://jjdconsultancy.com/] Jane Owen at Jane Owen PR: [https://janeowenpr.com/] The House of Oria: [https://www.thehouseoforia.com/] Sunny Pal at Astella: [https://www.instagram.com/astellajewellery/?hl=en] HLA Agency: [https://hlaagency.co.uk/] Films mentioned in this episode: Die, My Love, Lynne Ramsay Eleanor the Great, Scarlett Johansson The History of Sound, Oliver Hermanus Mastermind, Kelly Reichardt My Father's Shadow, Akinola Davies Pillion, Harry Lighton Romería, Carla Simón Sirât, Oliver Laxe Sorry Baby, Eva Victor Sound of Falling, Mascha Schilinski The Secret Agent, Kleber Mendonça Filho Sign up to the Girls On Film newsletter below: http://eepurl.com/iEKaM-/ or email girlsonfilmsocial@gmail.com to be signed up. Become a patron of Girls On Film on Patreon here: www.patreon.com/girlsonfilmpodcast Follow us on socials: www.instagram.com/girlsonfilm_podcast/ www.facebook.com/girlsonfilmpodcast www.twitter.com/GirlsOnFilm_Pod www.twitter.com/annasmithjourno Watch Girls On Film on the BFI's YouTube channel: www.youtube.com/playlist?list=PLX…L89QKZsN5Tgr3vn7z Girls On Film is an HLA production. Host: Anna Smith Executive Producer: Hedda Lornie Archbold, who also produced this episode Audio Editor: Benjamin Cook Intern: Hattie Morris Principal Partners: Vanessa Smith and Peter Brewer © HLA Agency

Lella Erludóttur í Hlaðvarpinu hjá Óla Jóns Um Lellu Lella Erludóttir lýsir sér sem "konu margra hatta" - hún er markþjálfi, mannauðssérfræðingur og hefur reynslu sem markaðskona. Hún starfar nú sem sjálfstætt starfandi markþjálfi og segir markaðsþekkingu koma sér alltaf að notum, hvort sem það er í starfi eða daglegu lífi. Hvað er markþjálfun? Lella útskýrir markþjálfun sem sannreynda viðtalsaðferð þar sem markþjálfinn hýsir rýmið og stýrir ferlinu, en markþeginn stýrir viðfangsefninu. Markþjálfinn spyr kraftmiklar og ögrandi spurningar til að efla vitundarsköpun hjá markþeganum. Grundvallartrú markþjálfunar er að hver og einn markþegi sé hæfur, skapandi, úrræðagóður og hafi öll svörin innra með sér. Sérhæfing Lellu Lella hefur þrengt markhóp sinn og sérhæft sig í: * Starfstengdri markþjálfun * Loddaralíð (imposter syndrome) - þar sem fólk líður eins og það sé að feika það og óttist að aðrir komist að "hinu sanna" Hún rekur sex klukkustunda námskeið um loddaralíð og tekur fólk í markþjálfun sem glímir við þetta vandamál. Starfstengd tímamót Lella vinnur mikið með fólk sem er að upplifa starfstengd tímamót: * Þá sem vilja meiri ábyrgð eða fleiri verkefni * Fólk sem vill skipta um starf eða veit ekki hvað það vill gera * Þá sem eru að jafna sig eftir veikindi eða kulnun * Fólk sem flytur aftur til landsins Faglegar vottanir Lella tilheyrir ICF (alþjóðasamtökum markþjálfa) með PCC vottun, sem þýðir: * ACC: Grunnmenntun + 100 klukkustundir í markþjálfun * PCC: 175 klukkustundir menntun + 500 klukkustundir markþjálfun * MCC: Enn meiri menntun + 2.500 klukkustundir markþjálfun NBI huggreiningar Lella er vottuð til að gera NBI huggreiningar sem mæla hugsnið í fjórum flokkum: * Gulur: Skapandi, lausnamiðað, opinn * Rauður: Félagslegur, mannlegur, tengsl * Grænn: Verndandi, skipulagður * Blár: Raunsær, staðreyndamiðaður Þetta tæki er hægt að nota á einstaklinga og teymi til að skilja vinnustaðamenningu betur. Vinnustaðamenning Lella útskýrir vinnustaðamenningu sem það hvernig samskipti fara fram og ferlar virka í raun og veru - ekki bara það sem stendur á veggnum. Hún leggur áherslu á að vinna þurfi með menningu frá grunni og upp, og að bæði leiðtogar og starfsfólk þurfi að vinna sína vinnu. Jafnvægi vinnu og einkalífs Frekar en að tala um jafnvægi lítur Lella á það að vinna og einkalíf ættu að styðja hvort við annað - vera samofin þannig að hvort um sig veiti virði og næringu. Helstu viðskiptavinir Lella segist aðallega fá til sín konur á einhvers konar tímamótum sem eru í aðstæðum sem þeim líður ekki vel í og vilja breytingar en vita ekki hvað eða treysta sér ekki til að sækjast eftir tækifærum. Árangursdæmi Lella nefnir dæmi um konu sem kom til hennar með það í huga að þurfa að sitja í óþægilegu starfi næstu 30 árin. Eftir sex tíma í markþjálfun hafði konan skýra sýn á hvað hún vildi, sagði upp starfi sínu og fékk að lokum starf sem stjórnandi í fyrirtæki þar sem henni líður vel. Hvar finn ég Lellu? https://www.lella.is/ https://www.facebook.com/lella.markthjalfi https://www.linkedin.com/in/lellaerludottir/ https://www.instagram.com/lella.markthjalfi/ https://www.tiktok.com/@lella.markthjalfi Viðtalið sýnir hvernig markþjálfun getur hjálpað fólki að finna skýrleika, sjálfstraust og stefnu í starfi og lífi.

Host Anna Smith brings you an exclusive conversation with the women of Mission: Impossible – The Final Reckoning, recorded live at London's Ham Yard Hotel. This latest instalment in the high-octane Mission: Impossible franchise sees Ethan Hunt and the IMF team race against time to confront the Entity, a rogue artificial intelligence threatening global destruction. Joining Anna for this special panel are two talents at the heart of the action: Pom Klementieff, who takes on the role of Paris, and Angela Bassett, returning as Erika Sloane, the President of the United States. Together, they delve into the challenges of working on one of cinema's most physically demanding franchises, explore the critical role costume design plays in shaping their characters, and reflect on the powerful, real-world impact of casting a Black woman as the US president in a fictional universe. Sign up to the Girls On Film newsletter below: http://eepurl.com/iEKaM-/ or email girlsonfilmsocial@gmail.com to be signed up. Become a patron of Girls On Film on Patreon here: www.patreon.com/girlsonfilmpodcast Follow us on socials: www.instagram.com/girlsonfilm_podcast/ www.facebook.com/girlsonfilmpodcast www.twitter.com/GirlsOnFilm_Pod www.twitter.com/annasmithjourno Watch Girls On Film on the BFI's YouTube channel: www.youtube.com/playlist?list=PLX…L89QKZsN5Tgr3vn7z Girls On Film is an HLA production. Host: Anna Smith Executive Producer: Hedda Lornie Archbold Producer: Charlotte Matheson Intern: Anna Swartz Audio editor: Alex Jones Sound recordist: Erin Millican House band: MX Tyrants This episode is in partnership with Netflix © HLA Agency

Við ræðum við stjórnanda hlaðvarpsins Ein pæling, Þórarinn Hjartarson. Hlaðvörp skipta æ meira máli í þjóðfélagsumræðunni og við ætlum að ræða við stjórnendur hlaðvarpa í Lestinni næstu vikurnar.

Í dag byrjum við þáttinn á umfjöllun um vímuefnaröskun, sem er einn alvarlegasti heilbrigðisvandinn sem við glímum við – samkvæmt Alþjóðaheilbrigðisstofnuninni. Röskunin er þó meðhöndlanleg og við eigum meðferðir sem virka – en röskunin einkennist ekki síst af bakföllum og hindranirnar sem blasa við þeim sem sækja sér meðferð eru margar. Erla Björg Sigurðardóttir, lektor í félagsráðgjöf og framkvæmdastýra á áfangaheimili fyrir konur, Helena Gísladóttir, dagskrárstjóri meðferðar Krýsuvíkursamtakanna og MA-nemi í félagsráðgjöf og Sara Karlsdóttir löggiltur áfengis og vímuefnaráðgjafi og dagskrárstjóri meðferðar hjá Hlaðgerðarkoti setjast hjá okkur og ræða um félagslega stöðu einstaklinga í langtíma meðferð vegna vímuefnaröskunar. Hvað á að gera við rafhlöðuna úr rafmagnsbílnum þegar hann er hættur að ganga? Rúnar Unnþórsson, prófessor í iðnaðar- og vélaverkfræði við Háskóla Íslands, leitar nú svara við því en búast má við að innan fárra ára hafi fallið til mikið af slíkum rafhlöðum sem vel gætu átt gott og farsælt framhaldslíf. Og í lok þáttar ætlar Helga Lára Þorsteinsdóttir, safnstjóri RÚV, að kíkja við og deila með okkur gullmola úr safni Ríkisútvarpsins. Tónlist úr þættinum: Bridgers, Phoebe - Motion sickness. Fleet Foxes - Battery Kinzie. Stuðmenn - Vorið.

In this star-studded episode, Anna Smith and co-founder Hedda Lornie Archbold delve into two exciting new films led by complex and captivating women. First, Anna chats with Julia Louis-Dreyfus and Geraldine Viswanathan, stars of Thunderbolts*—the latest Marvel Cinematic Universe film. Together, they discuss their first meeting, stepping into a superhero world alongside Florence Pugh and bringing depth and humour to their roles. Then, Hedda speaks with producer Rosie Fellner and actor Elizabeth Reaser about The Uninvited—a darkly funny and deeply poignant film that explores gender, aging, and identity in Hollywood. Reaser portrays Rose, a once-famous actress whose life is upended by a mysterious guest at a glamorous Hollywood gathering. The film also stars Walton Goggins, Lois Smith, Eva De Dominici, Pedro Pascal, and Rufus Sewell, and is writer-director Nadia Conners' debut feature. Thunderbolts* landed in UK cinemas 1 May 2025 The Uninvited is in UK cinemas 9 May 2025 http://eepurl.com/iEKaM-/ or email girlsonfilmsocial@gmail.com to be signed up. Become a patron of Girls On Film on Patreon here: www.patreon.com/girlsonfilmpodcast Follow us on socials: www.instagram.com/girlsonfilm_podcast/ www.facebook.com/girlsonfilmpodcast www.twitter.com/GirlsOnFilm_Pod www.twitter.com/annasmithjourno Watch Girls On Film on the BFI's YouTube channel: www.youtube.com/playlist?list=PLX…L89QKZsN5Tgr3vn7z Girls On Film is an HLA production. Host: Anna Smith Executive Producer: Hedda Lornie Archbold Producer: Charlotte Matheson Intern: Hattie Morris Audio editor: Benjamin Cook House band: MX Tyrants Principal Partners: Vanessa Smith and Peter Brewer © HLA Agency

Our Lawyer, Jim Pocrass, assesses the lawsuit brought by Streetsblog Los Angeles editor Joe Linton. LA Metro has argued that because it's not the city, it doesn't have to make bike infrastructure when repaving city streets, as called for in ballot measure HLA. The agency claims it would have to destroy homes and buildings to both preserve parking and make space for bikes (3:40). The standoff between New York and the Federal government over congestion pricing, as told by Streetsblog NYC Editor Gersh Kuntzman (10:22). Bike JC's Vice President Tony Borelli, Trustees Emmanuelle Morgan and Deidre Newman, and bike maker Anke Irmscher on Jersey City's bike ecosystem and their place in it. (23:50).

In this episode Ethan, Nic, and Sully discuss the closure of Pike Place Market to cars, LA Metro's light rail expansion to LAX, and the idea of Freedom Cities. They explore housing challenges in cities like Baltimore and Philadelphia, the HLA lawsuit in Los Angeles, and the difficulty of making public transit profitable. The conversation highlights the importance of headways, accountability in urban planning, and balancing the roles of cars, transit, and AI in city governance.Send us a question: radiofreeurbanism@gmail.comPatreon: patreon.com/RadioFreeUrbanism Instagram: https://rb.gy/ezn9rzSully: https://www.youtube.com/@SullyvilleEthan: https://www.youtube.com/@climateandtransitNic: https://www.youtube.com/@nicthedoorLinksBest Side Cycling - Car Free Pike Place: https://www.youtube.com/watch?v=aVCvnZnqyEIFreedom Cities: https://tinyurl.com/2z8carjbHLA Lawsuit: https://www.streetsforall.org/blog/first-hla-lawsuit

VidRay deals with his son hitting milestones, and Ray becomes competitive. Brad never watched Free Willy. Chuck wonders what would overshadow Will Smith's Oscars Slap and bring him back to Hollywood dominance?Also: Edge of Tomorrow, the Cruel Intentions kiss, WWE's HLA, American Pie and ultimately - the death of the teen sex comedy.Video edit by Craig Depina@funbearablepod / funbearablepod.com-------------------------------This episode is brought to you by NARRAGANSETT BEER! Check out Narragansett Beer nationally and make sure to check out the new Narragansett brewery in Providence, RI if you're in the New England area!narragansettbeer.com / @gansettbeer-------------------------------#podcast #laugh #funny #movies

News: Healthy Streets LA, the ballot measure which requires Los Angeles to implement bike infrastructure every time city streets are repaved, is being ignored by the county's transportation agency, LA Metro. Taylor talks with the founder of Streets For All, Michael Schneider, who led the HLA campaign, and the Editor of Streetsblog LA, Joe Linton, who's now suing the city (1:33). It's been 100 years since the Los Angeles city council passed the ordinance which said that if you're walking you have to give right of way to drivers everywhere, except for particular crossings. New Mexico adopted the Stop as Yield Law for cyclists. Paris reduced speed limits on the Boulevard Périphérique from 70 to 50 km/hr, resulting in reduced traffic congestion, smoother traffic flow, fewer crashes, lower air pollution, and lower noise levels. https://www.apur.org/en/our-works/tracking-changes-boulevard-peripherique-and-green-belt-districts-october-2024-february-2025 London's Tweed Run ride is April 29. For National Autism Acceptance Month, Detroit's Neila Johnson has created the Cycling the Spectrum ride. Neila talks with Motown Trailblazers Bike Club President Reo Ramsey (24:35). Cross country solo cyclist Chris Casey tells the story of his ride across the U.S. (34:05). Bike Thought: The 85th Percent Rule, by Charles Marohn (54:36). Thanks Ted Rogers of BikinginLA.com.

Andrés Magnússon og Stefán Einar Stefánsson ræða um hrakfarir ríkisstjórnarinnar frá þvi að hún tók við völdum fyrir þremur mánuðum, almennt um stöðuna í stjórnmálum, hvort að Stefán Einar sé að stefna að því að verða bæjarstjóri í Garðabæ, hvort að það sé nýtt vandamál fyrir ríkisstjórnina í vændum, hvernig stjórnarandstaðan mun standa sig, um óviðeigandi spjallgrúbbur og margt annað sem vert er að fjalla um á afmælis-bjórkvöldi Þjóðmála. Hlaðvarp Þjóðmála fagnar nú fjögurra ára afmæli og það er af nægu að taka.

In this special episode recorded at the Glasgow Film Festival, Jessica Lange joins Girls On Film host Anna Smith to reflect on her extraordinary career across stage and screen. She discusses her latest film, Long Day's Journey Into Night, which premiered at the festival, and shares insights into her rural Minnesota upbringing, early years studying mime in Paris, and her upcoming role as Marlene Dietrich. Jessica also revisits some of her most iconic roles, from portraying Frances Farmer in the heartbreaking biopic Frances to starring alongside Dustin Hoffman in the genre-defying comedy Tootsie. She also explores her more recent work on American Horror Story, which not only cemented her status as an acting legend but also introduced her to a new generation of fans. Beloved by Gen X and Gen Z alike, Jessica's performances continue to captivate audiences across film, television and stage. Acclaimed as one of the greatest actresses of her generation, Jessica is the 15th Oscar winner to appear on Girls On Film. The conversation was recorded on 1 March 2025. http://eepurl.com/iEKaM-/ or email girlsonfilmsocial@gmail.com to be signed up. Become a patron of Girls On Film on Patreon here: www.patreon.com/girlsonfilmpodcast Follow us on socials: www.instagram.com/girlsonfilm_podcast/ www.facebook.com/girlsonfilmpodcast www.twitter.com/GirlsOnFilm_Pod www.twitter.com/annasmithjourno Watch Girls On Film on the BFI's YouTube channel: www.youtube.com/playlist?list=PLX…L89QKZsN5Tgr3vn7z Girls On Film is an HLA production. Host: Anna Smith Executive Producer: Hedda Lornie Archbold Producer: Charlotte Matheson Intern: Anna Swartz Audio editor: Alex Jones House band: MX Tyrants Principal Partners: Vanessa Smith and Peter Brewer © HLA Agency

As the organ transplant list continues to grow, experts in the transplant diagnostics industry are looking for ways to address the supply and demand challenges within the field. New tactics, like retransplantation and xenotransplantation, and new testing methods, such as HLA testing and transplant diagnostics, are being explored to boost transplant success rates and ensure more patients get the lifesaving transplants they need. As President of Thermo Fisher Scientific's transplant diagnostics division, Tina Liedtky is at the cutting edge of meeting this challenge. She's also passionate about addressing health equity issues, such as ingrained biases regarding gender and race, to help bridge the transplantation gap.Tina joined Meg for a fascinating discussion about the future of transplantation, closing 'the gap', and Thermo Fisher's recent award. Qualio website:https://www.qualio.com/ Previous episodes:https://www.qualio.com/from-lab-to-launch-podcast Apply to be on the show:https://forms.gle/uUH2YtCFxJHrVGeL8 Music by keldez

In this episode of Girls On Film, recorded at the 2025 Glasgow Film Festival, host Anna Smith is joined by co-founder and Executive Producer of the podcast, Hedda Lornie Archbold, to bring listeners exclusive interviews with some of the festival's stars. They welcome insights from Festival Director Allison Gardner, star of opening gala film Tornado, Kōki, and two of the creative minds behind The Extraordinary Miss Flower. Allison Gardner talks about her highlights of her final year leading the Glasgow Film Festival. Kōki, the rising star of Tornado, opens up about her role as the daughter of a Japanese puppeteer in John Maclean's thriller. And Emiliana Torrini and Caroline Catz dive into their work on The Extraordinary Miss Flower, a genre-blending love letter to love letters, set to Torrini's dreamy soundtrack. The Extraordinary Miss Flower will be released in the UK on 9 May 2025. Tornado will be available in cinemas from 23 May 2025. Glasgow Film Festival 2025 runs from 26 February to 9 March 2025. For more information on screenings and tickets, visit the Glasgow Film Festival website https://www.glasgowfilm.org/home March is International Women's Month, and this year also marks the 20th Anniversary of Birds Eye View Festival, now Reclaim the Frame, a charity championing women filmmakers. The festival will host a Weekender from 7–9 March 2025 at BFI Southbank and Regent Street Cinema, featuring events, screenings, and a special showing of Lollipop, which featured in episode 181 of Girls On Film. For more details, visit reclaimtheframe.org.Sign up to the Girls On Film newsletter below: http://eepurl.com/iEKaM-/ or email girlsonfilmsocial@gmail.com to be signed up. Become a patron of Girls On Film on Patreon here: www.patreon.com/girlsonfilmpodcast Follow us on socials: www.instagram.com/girlsonfilm_podcast/ www.facebook.com/girlsonfilmpodcast www.twitter.com/GirlsOnFilm_Pod www.twitter.com/annasmithjourno Watch Girls On Film on the BFI's YouTube channel: www.youtube.com/playlist?list=PLX…L89QKZsN5Tgr3vn7z Girls On Film is an HLA production. Host: Anna Smith Executive Producer: Hedda Lornie Archbold Producer: Charlotte Matheson Intern: Anna Swartz Audio editor: Benjamin Cook House band: MX Tyrants Principal Partners: Vanessa Smith and Peter Brewer © HLA Agency

Madam President and all-around Immunogenetics boss, Dr. Cathi Murphey joins the podcast to discuss recent CMS updates, guidance, and clarifications on HLA testing and personnel.

For more information, visit https://thecirsgroup.com CIRS, or Chronic Inflammatory Response Syndrome, is an illness usually caused by your genes. But there are two different genetic based tests you can get! One to determine your Genetic HLA Haplotype, and one to see what genes are up or down regulated. Both inform your treatment to varying degrees, so today we want to help you understand which does what and whether these tests make sense for you. For more information, support, and resources in your own CIRS healing journey, visit TheCIRSGroup.com TIME STAMPS: 0:00 Intro and disclaimer 1:05 The confusion between genetic haplotypes vs GENIE tests 2:00 HLA Genetic Haplotypes: what is that? 4:08 Why HLA testing is important 5:04 HLA does not change, and you'll probably need help to figure out what it is 6:42 Autoimmune genes vs CIRS genes 8:08 What is the GENIE test? 8:50 When should you get the GENIE test? 9:55 GENIE shows the expression of genes 11:30 What the GENIE can tell you 11:50 How to interpret your GENIE (hint: get help) 13:37 When and whether to test if you are tight on funds HELPFUL LINKS: Buy Jacie's book (and leave a review!): https://a.co/d/1uYwP0q The CIRS Summit: http://thecirssummit.com/ MyHouseMakesMeSick HLA calculator: https://www.myhousemakesmesick.com/hlacalc/ Our GENIE test episodes: https://youtu.be/bCNp9qNqWWc?si=Y0naeyaEGVUXYm5W https://youtu.be/OoiT7WZ_UJI?si=s6aUTNO3iLf9fKvQ Order the GENIE here: https://www.progenedx.com/product-index Book a consultation with Christian to interpret your GENIE: https://cirslab.circle.so/checkout/11-with-christian The CIRS Group: Join our support community: https://thecirsgroup.com Check out our instagram: https://www.instagram.com/thecirsgroup/ Find Jacie for carnivore, lifestyle and limbic resources: Instagram: https://www.instagram.com/ladycarnivory YouTube: https://www.youtube.com/@LadyCarnivory Blog: https://www.ladycarnivory.com/ Order Jacie's book! https://a.co/d/8ZKCqz0 Find Barbara for business/finance tips and coaching: Website: https://www.actlikebarbara.com/ Instagram: https://www.instagram.com/actlikebarbara/ YouTube: https://www.youtube.com/@actlikebarbara Jacie is a Shoemaker certified Proficiency Partner, NASM certified nutrition coach, author, and carnivore recipe developer determined to share the life changing information of carnivore and CIRS to anyone who will listen. Barbara is a business and fitness coach, CIRS and ADHD advocate, speaker, and a big fan of health and freedom. Together, they co-founded The CIRS Group, an online support community to help people that are struggling with their CIRS diagnosis and treatment.

In today's episode, we welcome back Dr. Amar Kelkar for part 1 of our two-part discussion on allogeneic transplant. In this episode, we discuss the fundamental approach to patient selection and stem cell source selection. As you all know from this series, allogeneic transplants play a pivotal role in the management of AML. Dr. Kelkar's pearls of wisdom help make this confusing topic so much more approachable!Episode contents: - What factors do we incorporate when considering a patient for allogeneic transplant? - How do we use HLA-matching?- What are the pros and cons of the different sources of stem cells? ****Get paid to participate in market research surveys: https://affiliatepanel.members-only.online/FOC_24?utm_campaign=FOC&utm_source=email&utm_medium=email** Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodesLove what you hear? Tell a friend and leave a review on our podcast streaming platforms!Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Google Podcast

In this live Fertility Expert Q and A , I'm joined by Dr. Andrea Vidali. I had the honor of interviewing him about Pregmune, a platform for patients to receive a Reproductive Immunology work-up with him. We dove into the 6 categories that are part of a reproductive immunology work-up: HLA testing, NK activity, Systemic Inflammation, Thrombophilia, Regulatory T-cell, and Autoimmunity. It was so fascinating to learn from the best today. I hope you will listen in! Read the full show notes on Dr. Aimee's website. Pregmune's website. Subscribe to my YouTube channel for more fertility tips! Subscribe to the newsletter to get updates Do you have questions about IVF?Click here to join Dr. Aimee for The IVF Class. The next live class call is on Monday, December 16th, 2024 at 4pm PST (7pm EST), where Dr. Aimee will explain IVF and there will be time to ask her your questions live on Zoom. Dr. Aimee Eyvazzadeh is one of America's most well known fertility doctors. Her success rate at baby-making is what gives future parents hope when all hope is lost. She pioneered the TUSHY Method and BALLS Method to decrease your time to pregnancy. Learn more about the TUSHY Method and find a wealth of fertility resources at www.draimee.org.

https://solvitryggva.is/ Vinirnir Helgi Jean Claessen og Hjálmar Örn Jóhannsson hafa í áraraðir verið að gera grínefni saman, en á löngum köflum gekk það brösulega. Hjálmar fór að vinna á leikskóla og Helgi fór í jakkaföt og vildi verða bissnessmaður. En dropinn holar steininn og í dag eru þeir í fullri vinnu við að gera grínefni, bæði í Hlaðvarpinu Hæhæ og Hjálmar fer í gervi Hvítvínskonunnar nær daglega. Hér ræða þeir Sölvi um mikilvægi þess að elta draumana, gefast ekki upp, hætta að láta álit annarra stýra sér og margt margt fleira. Þátturinn er í boði; Narfeyrarstofa - https://narfeyrarstofa.is/ Caveman - https://www.caveman.global/ H-Berg - https://hberg.is/ Nings - https://nings.is/ Myntkaup - https://myntkaup.is

 Hal Gill from Preds Radio Network joins the show to talk Preds. Hal previewed tomorrow night's game against the Blackhawks. Hla also shared his thoughts on the new call-up Zach L'Heureux. Listen to hear more.

Why You Should Listen:  In this episode, you will learn about the use of GENIE testing in Chronic Inflammatory Response Syndrome. About My Guest: My guest for this episode is Dr. Ritchie Shoemaker.  Ritchie Shoemaker, MD is a recognized leader in patient care, research, and an education pioneer in the field of biotoxin related illness.  While illness acquired following exposure to the interior environment of water-damaged buildings (WDB) comprises the bulk of Dr. Shoemaker's daily practice, other illnesses caused by exposure to biologically-produced toxins are quite similar in their “final common pathway.”  What this means is that while the illness might begin acutely with exposure to fungi, spirochetes, apicomplexans, dinoflagellates and cyanobacteria, for example, in its chronic form, each of these illnesses has similar symptoms, lab findings, and Visual Contrast Sensitivity (VCS) findings.  Taken together the inflammatory illness from each of these diverse sources is known as  Chronic Inflammatory Response Syndrome. Key Takeaways: What is GENIE? Is HLA-DR still relevant? What are the common triggers of CIRS?  Actinobacteria?  Endotoxins?  Mold and mycotoxins? What is hypometabolism? How does CIRS impact insulin and blood sugar? What is apoptosis? What is the role of coagulation in CIRS? Are upregulated cytokines seen in CIRS? Can GENIE identify those that may have Lyme? What are defensins? What is Ikaros? What is the role of MAP kinases in CIRS? What do Toll receptors tell us? How are B and T cells involved in CIRS? How many CIRS markers are needed in GENIE to suggest CIRS? What is the PTSD gene? How often is histamine involved? What are the cytoskeleton and microtubules?  What can be determined around the function of Treg cells? What are the recent additions to GENIE in the realm of Parkinson's disease? What has GENIE told us about MARCoNS? Connect With My Guest:  http://SurvivingMold.com Interview Date: September 11, 2024 Transcript: To review a transcript of this show, visit https://BetterHealthGuy.com/Episode205. Additional Information: To learn more, visit https://BetterHealthGuy.com. Disclaimer:  The content of this show is for informational purposes only and is not intended to diagnose, treat, or cure any illness or medical condition. Nothing in today's discussion is meant to serve as medical advice or as information to facilitate self-treatment. As always, please discuss any potential health-related decisions with your own personal medical authority.